|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||2.9300 - 3.0500|
|52 Week Range||1.6070 - 7.8940|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
There are a large number of publicly traded marijuana companies, with the biggest ones being located in Canada -- as Canada is the largest market where marijuana has been fully legalized, notes Ben Reynolds, editor of Sure Dividend in a special report on the best opportunities in the cannabis space.
CBD -- which is simply shorthand for cannabidiol -- is a non-psychoactive component of cannabis plants, explains Timothy Lutts, editor of Cabot Marijuana Investor.
There's no denying it: The legal marijuana trend is here to stay. And pot stocks are only gaining more momentum as legalization sweeps the nation (and the world).So then the question becomes, how do I invest? Do I buy the growers of "legal weed"? Financiers? How about the folks selling hemp? Or turning it into CBD oil? Do I invest here in the United States? Or abroad?The fact is, I see compelling investments in ALL of those areas - if done properly. I've made no secret of that.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo, how do we narrow it down? Let's start by simply comparing the valuations.Take Canopy Growth (NYSE:CGC) stock, for example, which just enjoyed its fifth birthday. From that humble IPO as "Tweed Inc.," it's now become one of the premier marijuana stocks since Canada legalized last year. Canopy is also enjoying a major influx of cash from a big investment by Constellation Brands (NYSE:STZ), and it's honing its brand by signing splashy deals with the likes of Martha Stewart and Snoop Dogg. * 7 High-Risk Stocks With Big Potential Rewards CGC stock has a current market cap of $14.9 billion on just $184 million in projected sales for 2019. That equates to a forward price-to-sales (P/S) ratio of 81.For context, even the likes of Facebook (NASDAQ:FB) and Netflix (NASDAQ:NFLX) have a forward P/S more like 9.That's something to consider before jumping on the bandwagon.Now, I realize that some investors are willing to pay up like this, to own the biggest names in an industry. But when it comes to marijuana stocks, some of them will actually make MORE in sales…yet are still "flying under the radar." That's where we can really make money.The Green Organic Dutchman (OTCMKTS:TGODF) certainly fits that bill. It's much newer than Canopy Growth, having just IPOed last May. It's smaller, too, at $890 million in market cap. From two facilities it's building in Ontario and Quebec, it will grow 255,700 pounds of cannabis per year.Those two facilities are strategically located to serve two-thirds of the Canadian population, and TGODF has some key partnerships with power generation firms. Both of which allow it to produce more cheaply than competitors. And by the time its product is extracted, purified, and made into oils, creams, edibles, foods, and more -- in addition to the marijuana flower itself -- TGODF is expected to turn in $280 million in sales for 2019.That comes out to a forward P/S of just 3.2.You can see how, if it gets even to half or a quarter of Canopy Growth's valuation, those of us who buy TGODF stock will find ourselves richly rewarded for investing in future production.What I especially like about this company is that it's uniquely positioned -- at the intersection of "legal weed" and the high demand (among millennials, in particular) for organic products.But I'm even more excited about Charlotte's Web (OTCMKTS:CWBHF), another small-cap cannabis stock with room for big upside. This one, in fact, was my pick for the InvestorPlace Best Stocks for 2019 contest.CWBHF is certainly not one of your typical "pot stocks." This one is a pure play on cannabidiol (CBD), an extract of hemp that is non-psychoactive. So, while it doesn't get you high, it does have the anti-inflammatory and pain-relieving properties that folks are looking for in medical marijuana products.I've talked at length about CWBHF stock and its origins in dramatically reducing a little girl's debilitating seizures. It's such a cool story.And the numbers are quite solid, too.As one of the first reputable CBD producers -- and the number-one brand, by market share, of hemp-based CBD -- Charlotte's Web is expected to generate $176 million in sales this year.With its current $2 billion market cap, that puts CWBHF stock at just an 11.3 forward P/S…even after a 124% climb in 2019 to date.And that's before it gets onto the shelves of a major retailer.Once it signs a distribution deal with Walmart (NYSE:WMT), CVS Health (NYSE:CVS), or Walgreens (NASDAQ:WBA) -- and the latter two are already on the prowl -- Charlotte's Web will soar even higher. Given that this is one of the only CBD companies with the ability to supply a large retailer, I see this as inevitable.There's another event on the horizon that will make CWBHF stock go parabolic:Charlotte's Web CEO Hesaam Moallem has already made it clear that he's ready to go from the minor leagues to the major leagues……in a move that will open up the floodgates to mutual funds, ETFs, and institutional cash.And he's not the only one.I'm hard at work on my next presentation to investors like you -- all about this particular market anomaly…one that's sending certain cannabis stocks up over 1,000%.With so many of them still so cheap, as we just saw, I'm confident in making that call. And those gains will not involve options or any unnecessary risk.I'll be holding this Cannabis Stock Summit at 7 p.m. ET tomorrow (Tuesday, April 9). Click here to reserve your spot by visiting my event site.My team and I have been working on the strategy behind it for the last year…and could not believe what we discovered. It is now time to share this with you. * I'll show why you haven't missed out on the cannabis boom and how the biggest gains are still ahead of us… * I'll reveal how some of our readers have been able to see over 1,000% gains in cannabis stocks, without any use of options or any unnecessary risk. * And you'll walk away with a free stock name and symbol that my research shows could jump 1,000% in the near future.To reserve your seat and get up to speed on everything, simply click here.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Data Center Buys That Deliver Sizable Income * 7 High-Risk Stocks With Big Potential Rewards * 3 Marijuana Stocks to Watch as New York, New Jersey Delay Legalization Compare Brokers The post Why the Smallest Pot Stocks Pack the Biggest Wallop appeared first on InvestorPlace.
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , April 8, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...
One sector getting a major boost from cannabis is solar energy, partly due to the high energy requirements of indoor grow facilities and the cannabis industry. The company is one of the US's top microgrid solutions according to Navigant Research, who added them to their top 10 in 2018. Today we are highlighting a variety of Cannabis Plays, including: CleanSpark, Inc. (CLSK), The Green Organic Dutchman Holdings Ltd. (TGODF), New Age Beverages Corporation.
Over the long run, I remain net bullish on legal marijuana. However, my optimism for the sector doesn't cloud reality. I can see as plain as daylight that the honeymoon phase is over. Now, companies like Aurora Cannabis (NYSE:ACB) must provide the goods. If not, ACB stock could face serious trouble.Source: Shutterstock Unfortunately, this isn't just a hypothetical musing.After jumping to a tremendous start to 2019, Cronos Group (NASDAQ:CRON) started to weaken ahead of its fourth-quarter earnings report. On the disclosure of the financial print, Cronos rang up disappointing revenue. As a result, shares slipped badly.InvestorPlace - Stock Market News, Stock Advice & Trading TipsOn the one hand, it's questionable if CRON can recover in the nearer term. On the other hand, Aurora Cannabis stock presents a contrasting picture. On a year-to-date basis, shares are up over 85%. Not only that, ACB is one of few publicly traded cannabis firms that has generated shareholder profits every month thus far.How does ACB stock stand out from the competition? Primarily, management consistently delivers ridiculous sales growth. For instance, in its most recent fourth-quarter earnings report, the company generated 54.2 million CAD. Against the year-ago level, revenue had skyrocketed 363%. * 5 Cannabis Stocks Set to Skyrocket -- According to Wall Street's Top Analysts However, not everything about Aurora Cannabis stock embodies confidence, which is why shares have sometimes exhibited volatility. For instance, in Q4 2018, analysts recognized a glaring defect in Aurora's numbers, and management disclosed losses of nearly 238 million CAD.In Q4 2017, Aurora only mustered 11.7 million in sales. However, they translated that comparatively small haul into 7.7 million in profits. With the latest earnings result, it appears Aurora is taking one step forward and two steps back.Understandably, stakeholders and prospective buyers in ACB stock want a clearer and more consistent picture before diving into Aurora shares. But if you've got the nerve, Aurora is one of the most credible names in the sector. Multi-Layered Tailwinds Boost ACB StockWhenever anyone discusses Aurora Cannabis stock, one of the top bullet points is production capacity. According to its website, Aurora has 11 production facilities, translating to a total funded capacity exceeding 500,000 kilograms a year.To put that into context, ACB's only real rival in this space is Canopy Growth (NYSE:CGC), which forecasts similar figures. But from there, the competition drops off dramatically. Although they round out the top four, Aphria (NYSE:APHA) and Green Organic Dutchman (OTCMKTS:TGODF) can only produce approximately 255,000 kilos and 195,000 kilos, respectively.But it's not just outright capacity that makes ACB stock shine. Rather, management has made in my opinion strategically powerful decisions. A prime example is Aurora's buyout of Whistler Medical Marijuana. Several critics blasted the move due to Whistler's puny 5,000 kilos of annual production.What they overlooked was Whistler's specialty, which isn't focused on quantity, but rather quality. The acquired company features an extensive genetics bank from which they produce strain-specific products.This is a critical point because growing marijuana isn't rocket science. But finding the right strain to address certain ailments? That's very much a vital skill set, and the Whistler buyout will help distinguish Aurora Cannabis stock.Combined, ACB is better positioned than most to advantage the U.S. government's slow but steady progress toward full legalization. While I don't want to make too many bold predictions about our political landscape, the signs certainly justify optimism.And what if the rest of the world opened to legalization? That would definitely spike ACB stock. Better yet, it's not out of the realm of possibility. Last year, Thailand and South Korea -- which are both conservative countries -- legalized medical cannabis. Although heavy restrictions apply, these are unprecedented examples of forward thinking. Don't Shy Away From ACB StockDespite making my pitch for ACB stock, it pays to have a cautious approach. Unlike other industries, cannabis is extremely emotional. Bad news travels very quickly here, and sometimes unfairly.Plus, you're talking about an investment that has soared in a very short period. I don't care what it is, nothing rises indefinitely without incurring a correction. Given sector fears and concerns about sustainability, I wouldn't be surprised if Aurora Cannabis stock takes a hit.But if it does, you can bet that I'll be eyeballing my desired entry point. When you have both capacity and credibility in this segment, you're more likely to win out in the long run.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Tech Stocks That Transformed Their Business * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 7 Weak Blue-Chip Stocks to Trim Immediately Compare Brokers The post Marijuana Stocks Look Frothy, But Aurora Stock Is Well-Prepared appeared first on InvestorPlace.
Company executives share vision, answer questions live at VirtualInvestorConferences.com NEW YORK , March 28, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the agenda for the upcoming ...
HAMILTON, ON , March 28, 2019 /CNW/ - The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGOD") (TGOD.TO) (TGODF) is pleased that Hamilton City Council has voted to approve the Company's settlement offer, to allow TGOD to operate its cannabis greenhouse in Ancaster, Ontario upon confirmation of the settlement by the Local Planning Appeal Tribunal at a meeting scheduled for April 25, 2019 . "This is tremendous news for our Company and for the city of Hamilton ," said Brian Athaide , CEO and Director of TGOD.
Despite forecasting 219,000 kilos of peak annual production, this grower hardly has any revenue to show for it.
What Drove Curaleaf’s Stock Price Last Week?(Continued from Prior Part)Stock performances Despite the weakness in the broader equity market last week, with the S&P 500 Index falling 0.8%, most cannabis stocks delivered positive returns. From
TORONTO , March 25, 2019 /CNW/ - The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGOD") (TGOD.TO) (TGODF) is pleased to announce that effective today sales of certified-organic cannabis have started with national distribution to medical patients. The Growers' Circle is a select group of patients across Canada now receiving TGOD's first certified-organic flower. The Growers' Circle launch is a limited production rollout of the Company's premium product, allowing TGOD to perfect its distribution ahead of its production ramp-up and scaled rollout this year.
Cannabis stocks fall, as investors scrutinize earnings from Green Organic Dutchman Holdings Ltd. and await a U.S. congressional committee vote next week on protecting banks that serve the sector.
HENDERSON, NV / ACCESSWIRE / March 20, 2019 / With cannabis in the news and investors becoming more and more hungry for the next big winner in the industry, we decided to highlight a couple that could ...
The Green Organic Dutchman Holdings Ltd. said it had a net loss of C$45.2 million ($33.9 million), or 21 cents a share, for 2018, wider than the C$13.5 million loss, or 12 cents a share, posted in the year-earlier period. Revenue came to C$1.9 million, as the company booked its first quarterly revenue following the acquisition of HemPoland on Oct. 1 and the full legalization of cannabis in Canada on Oct. 17. The company did not provide a net loss for the quarter, but said its loss from operations came to C$18.1 million due to the costs of ramping up operations, consumer research and administration related to gearing up for commercial production in 2019. The company ended the year with C$263.5 million of cash, which will be used to fund expansion and international growth. Jefferies analyst Owen Bennett said costs came in "significantly below estimates. You could take a positive or negative view of this (encouraging re route to profitability or not spending much around brand awareness)," he wrote in a note to clients. "First real financial catalyst will be next quarter with further re-rating potential if they execute." Bennett rates the stock a buy with a price target of C$6.10, compared with its current trading level of C$5.48. U.S.-listed shares were down 0.5% in premarket trade, but have gained 128% in 2019 so far, while the S&P 500 has gained 4%.
TORONTO , March 19, 2019 /PRNewswire/ - The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGOD") (TSX: TGOD) (US:TGODF) is pleased to report its financial and operational ...
The cannabis carnival continues.As we've pointed out these past few weeks, Jefferies analyst Owen Bennett seems to have developed an interest in cannabis ... stocks, initiating coverage on at least 10 of them since he first began assigning ratings on Feb. 25. Yesterday, Bennett delved a little deeper into the industry to update investors on recent happenings in this happiest of industries.Bennett's update concerns Mississauga, Canada-based cannabinoid oil R&D shop The Green Organic Dutchman (TGOD), which the analyst included in its initial survey of the industry last month. TGOD has just signed a multi-year "extraction service agreement" with fellow Canadian cannabis researcher Valens GroWorks.Under the terms of their deal, TGOD will provide "cannabis and hemp biomass" and Valens will "process, extract and purify" same, providing TGOD with "concentrated cannabinoid resins and distillates to produce oils, sprays and capsules as well as oils for vaporization and future edible, beverage and topical products."This contract will initially run for two years, and if and when Valens succeeds in obtaining certification of its processing methodologies as "organic," it agrees to produce organic cannabinoid resins (etc.) exclusively TGOD for a term of one year. This could give TGOD a leg up over any competitors unable to get access to a supply of such organic-labeled marijuana-derived consumables.And yet, Bennett actually views this news as a negative.As Bennett explains, TGOD has been targeting production of perhaps 60,000 kg of cannabis derivatives by year-end. Despite this objective, the analyst was already concerned that TGOD might be unable to produce sufficient CBD volumes to take full advantage of cannabis "derivatives" legalization, if and when it occurs. In the analyst's view, the deal suggests that production remains a problem for TGOD -- enough so that it's had to seek outside help from Valens -- and "this could be a possible negative" for TGOD.Bennett rates TGOD a Buy with a C$6.10 price target, which implies nearly 40% upside from current levels. (To watch Bennett's track record, click here)Meanwhile in Germany ...In other news, Bennett notes that Aurora Cannabis (ACB) has begun selling cannabis oil into the German medical market, where together it, and Tilray, are now believed to be the only producers supplying both marijuana flower and derivatives. The analyst views Germany as a "key" market to making cannabis an international growth industry, citing both "strong patient growth" and high margins on marijuana sales into the Teutonic state as making Germany an attractive market.Meanwhile, Bennett points out, Canadian companies' international sales of cannabis in 2018, outside of Canada, were "broadly similar to the weekly sales seen in Colorado."Let me repeat that: What (legal) marijuana sellers sold in one week, in one U.S. state last year, equaled what Canadian marijuana producers sold (legally) in all of the rest of the world, combined, in one year. In an exercise of droll understatement that would do a British banker proud, Bennett calls this sales performance "underwhelming."Now, the flip side of this is that winning a large market such as Germany could yield large growth off of a very small sales base. Seen in this light, even the fact that Aurora is just beginning to sell into this market has to be seen as a positive for the stock.Overall, Bennett rates ACB stock a Buy with C$12.00 price target, suggesting the stock has about 17% upside from where it's currently trading.For more insights, check out our cannabis stocks category. More recent articles from Smarter Analyst: * Lyft (LYFT) Faces the Public; Should You Buy the Stock? * Is Microsoft (MSFT) Stock Still a Strong Pick for Growth? * This Undexpected Apple (AAPL) Announcement Justifies the Potential of Services Revenue * Think Twice Before You Buy Tesla (TSLA) Stock, Analyst Says
Investorideas.com, a leading investor news resource covering hemp and cannabis stocks releases a snapshot looking at the growing number of cannabis companies expanding their CBD capabilities, following the major market trends for 2019. Every company and investor in the cannabis industry is well aware of the hype surrounding the potential for CBD and hemp. The momentum of CBD is making everyone take notice and many cannabis companies are not wasting this momentum for CBD, investing in new partnerships and business changes to ensure a strong position for the future.
Cannabis sales have been soaring since legalization in Canada but there's a lot more to come as the industry continues to change. Here are some of the hottest cannabis stocks right now that are positioning themselves to take advantage of the fast-growing retail market. Westleaf has been making a name for itself in the industry as it looks to become a dominant force in the retail market.
TORONTO , March 11, 2019 /CNW/ - The Green Organic Dutchman Holdings Ltd. (the "Company" or "TGOD") (TGOD.TO) (TGODF) is pleased to announce that it has entered into a multi-year extraction services contract with Valens GroWorks Corp. (CSE:VGW) (VGWCF) ("Valens"). Valens is a licenced provider of cannabis products and services specializing in various proprietary extraction, distillation, cannabinoid isolation and purification technologies. Partnering with Valens will accelerate TGOD's Canadian hemp strategy and allow for early market entry of TGOD's organic hemp-derived CBD product lines within the coming months.
KELOWNA, BC , March 11, 2019 /CNW/ - Valens GroWorks Corp. (VGW.CN) (VGWCF) (the "Company" or "Valens"), a multi-licensed, vertically integrated provider of cannabis products and services focused on various proprietary extraction methodologies, distillation, cannabinoid isolation and purification, as well as associated quality testing is pleased to announce that it has entered into a multi-year extraction services agreement (the "Agreement") to provide cannabis and hemp extraction services to The Green Organic Dutchman Holdings Ltd. ("TGOD") (TGOD.TO) (TGODF), a premium global organic cannabis company with operations focused on medical cannabis markets in Canada , Europe , the Caribbean and Latin America , as well as the Canadian adult-use market.
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / Below are several cannabis stocks with possible upside. One is THC Therapeutics, Inc. (THCT) . The US patent office has recently accepted ALL 20 claims for ...